(NASDAQ: ALDX) Aldeyra Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.81%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.82%.
Aldeyra Therapeutics's earnings in 2026 is -$27,369,779.On average, 7 Wall Street analysts forecast ALDX's earnings for 2026 to be -$22,644,529, with the lowest ALDX earnings forecast at -$37,833,374, and the highest ALDX earnings forecast at -$13,934,167. On average, 6 Wall Street analysts forecast ALDX's earnings for 2027 to be -$13,843,685, with the lowest ALDX earnings forecast at -$16,552,101, and the highest ALDX earnings forecast at -$10,133,939.
In 2028, ALDX is forecast to generate -$5,229,837 in earnings, with the lowest earnings forecast at -$8,276,051 and the highest earnings forecast at -$1,900,114.